RESUMO
La metformina (biguanida), grupo de medicamentos que proceden de la guanidina, se ha utilizado desde época medieval para tratamiento de la diabetes. Esta revisión bibliográfica narrativa tiene el propósito de contribuir a mejorar su uso clínico. Se realizó búsqueda de artículos originales, revisiones sistemáticas y artículos de revisión en internet, período 2012-2018, o anterior si fuera relevante. La metformina actúa como un hipoglucemiante, reduce la producción hepática de glucosa inhibiendo la gluconeogénesis y la glucogenólisis, aumenta captación de glucosa a nivel muscular y disminuye absorción de glucosa a nivel gastrointestinal. Una vez intracelular, aumenta la glucólisis anaerobia, uno de sus principales efectos adversos. La metformina es un fármaco que genera incremento de sensibilidad a insulina, mayor control de la glucemia, mejoría del perfil lipídico y de la función vascular, es de bajo costo y es en la actualidad la primera opción en el tratamiento de la diabetes mellitus tipo 2...(AU)
Assuntos
Humanos , Biguanidas/farmacocinética , Diabetes Mellitus/diagnóstico , Metformina/uso terapêutico , Hipoglicemiantes/uso terapêuticoRESUMO
OBJECTIVES: Platelet rich fibrin (PRF) is an autologous fibrin glue, produced from patients' blood, which, besides intraoperative use, has applications in the treatment of infected wounds. The combination with antimicrobial agents results in a prolonged antibacterial effect allowing for wound dressing change intervals of seven days even in infected wounds. The aim of this study was to evaluate release kinetics of amikacin, teicoplanin or polyhexanide from a PRF-layer. METHODS: PRF mixed with teicoplanin, amikacin or polyhexanide was sprayed on a silicon gauze patch and put on a colombia agar with bacteria with known minimal inhibitory concentration (MIC) and incubated for 24 hours and afterwards transferred to another agar with the same bacterial strain. Inhibition zones were measured every 24 hours. This was repeated on 7 consecutive days. Antibiotic concentrations were calculated by interpolation. RESULTS: More than 1000 mg/L teicoplanin were released within the first 24 hours and 28.22 mg/L after 168 hours. Amikacin release was above 10,000 mg/L within the first 24 hours and still 120.8 mg/L after 120 hours. A release of polyhexanide could be verified for the first 24 hours only. Consequently teicoplanin and amikacin released from PRF showed antimicrobial in-vitro effects for almost a week, whereas an antimicrobial effect of polyhexanide could only be verified for the first 24 hours. CONCLUSIONS: Our Results show that a weekly dressing regimen may be justified in wounds treated with PRF plus amikacin or teicoplanin, since bacteria will be eradicated over a considerable period of time after a single application of PRF.
Assuntos
Amicacina/farmacocinética , Antibacterianos/farmacocinética , Biguanidas/farmacocinética , Preparações de Ação Retardada/farmacocinética , Fibrina/farmacologia , Teicoplanina/farmacocinética , Ágar/química , Amicacina/farmacologia , Antibacterianos/farmacologia , Bandagens , Biguanidas/farmacologia , Preparações de Ação Retardada/farmacologia , Testes de Sensibilidade a Antimicrobianos por Disco-Difusão , Liberação Controlada de Fármacos , Humanos , Klebsiella pneumoniae/efeitos dos fármacos , Klebsiella pneumoniae/crescimento & desenvolvimento , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Staphylococcus aureus Resistente à Meticilina/crescimento & desenvolvimento , Modelos Biológicos , Fator de Crescimento Derivado de Plaquetas/farmacologia , Plasma Rico em Plaquetas/química , Pseudomonas aeruginosa/efeitos dos fármacos , Pseudomonas aeruginosa/crescimento & desenvolvimento , Teicoplanina/farmacologia , Cicatrização/efeitos dos fármacosRESUMO
A new biodegradable coating was developed for bioabsorbable monofilament sutures. Specifically, a random copolymer having 35wt-% and 65wt-% of lactide and trimethylene carbonate units showed appropriate flexibility, stickiness and degradation rate, as well as capability to produce a complete and uniform coating. Monofilament sutures of polyglycolide-b-poly(glycolide-co-trimethylene carbonate-co-ε-caprolactone)-b-polyglycolide were loaded with chlorhexidine (CHX) and poly(hexamethylene biguanide) (PHMB) to explore the possibility to achieve antimicrobial activity without adverse cytotoxic effects. To this end, two processes based on single drug adsorption onto the suture surface and incorporation into the coating copolymer were used and subsequently evaluated. Although the second process could be considered more complex, clear benefits were observed in terms of drug loading efficiency, antimicrobial effect and even lack of cytotoxicity. In general, drugs could be loaded in an amount leading to a clear bacteriostatic effect for both Gram-negative and Gram-positive bacteria without causing significant cytotoxicity. Release profiles of PHMB and CHX were clearly different. Specifically, adsorption of the drug onto the fiber surface which prevented complete release was detected for PHMB. This polymer had advantages derived from its high molecular size, which hindered penetration into cells, thus resulting in lower cytotoxicity. Furthermore, bacterial growth kinetics measurements and bacterial adhesion assays showed greater effectiveness of this polymer.
Assuntos
Antibacterianos , Biguanidas , Clorexidina , Escherichia coli/crescimento & desenvolvimento , Ácido Poliglicólico , Staphylococcus epidermidis/crescimento & desenvolvimento , Animais , Antibacterianos/química , Antibacterianos/farmacocinética , Antibacterianos/farmacologia , Biguanidas/química , Biguanidas/farmacocinética , Biguanidas/farmacologia , Células COS , Clorexidina/química , Clorexidina/farmacocinética , Clorexidina/farmacologia , Chlorocebus aethiops , Ácido Poliglicólico/química , Ácido Poliglicólico/farmacocinética , Ácido Poliglicólico/farmacologia , Células VeroRESUMO
OBJECTIVES: Carnitine/organic cation transporter 1 (OCTN1) is involved in gastrointestinal absorption and mitochondrial toxicity of biguanides in rodents, but its pharmacokinetic roles in humans are largely unknown. The purpose of this study was to clarify the transport activities of two major OCTN1 variants, L503F and I306T, for gabapentin and three biguanide drugs, metformin, buformin and phenformin. METHODS: HEK293 cells were transfected with OCTN1 gene, its variants, or vector alone, and the uptake and cytotoxicity of each drug were examined. KEY FINDINGS: Buformin was identified to be an OCTN1 substrate. Uptake of biguanides, especially metformin, mediated by OCTN1 variant L503F, which is commonly found in Caucasians, was much higher than that by the wild-type transporter (WT-OCTN1). Cytotoxicity of metformin was also greater in HEK293 cells expressing the L503F variant, compared with WT-OCTN1. Uptake of gabapentin mediated by OCTN1 variant I306T, which is commonly found in both Asians and Caucasians, was lower than that by WT-OCTN1, although uptake of the typical OCTN1 substrate ergothioneine was similar. CONCLUSION: Organic cation transporter 1 variant L503F transports biguanides, especially metformin, more efficiently than WT-OCTN1, whereas the I306T variant transports gabapentin less efficiently than WT-OCTN1, suggesting that the common OCTN1 variants may alter pharmacokinetics of these drugs.
Assuntos
Absorção Intestinal , Metformina/farmacocinética , Transportador 1 de Cátions Orgânicos/genética , Polimorfismo de Nucleotídeo Único , Aminas/metabolismo , Aminas/farmacocinética , Povo Asiático , Biguanidas/metabolismo , Biguanidas/farmacocinética , Transporte Biológico Ativo , Buformina/metabolismo , Buformina/farmacocinética , Carnitina/metabolismo , Ácidos Cicloexanocarboxílicos/metabolismo , Ácidos Cicloexanocarboxílicos/farmacocinética , Ergotioneína/metabolismo , Ergotioneína/farmacocinética , Gabapentina , Células HEK293 , Humanos , Metformina/metabolismo , Transportador 1 de Cátions Orgânicos/metabolismo , População Branca , Ácido gama-Aminobutírico/metabolismo , Ácido gama-Aminobutírico/farmacocinéticaRESUMO
Nephropathy remains an important complication of diabetes. This work was carried out to evaluate the protective effects of N-thioacetylbiguanidine on the diabetic rat kidney. Fifteen adult male Wistar rats were divided into two groups: Group I, control (n=5) and Group II, diabetic group (n=10). The latter was equally divided into two subgroups: IIa (diabetic control) and IIb (diabetic N-thioacetylbiguanidine treated). Specimens were taken from the renal cortex, processed and examined using light, immunohistochemical, ultrastructural and morphometric techniques.The renal cortices from diabetic animals showed dilated glomeruli and tubules and thickening of the glomerular capillary basement membranes. The proximal tubules revealed partial loss of brush border and deposition of PAS-positive material in some distal tubules. iNOS-immunoreactivity was strongly expressed in the renal tubules and glomeruli. The juxtaglomerular (JG) cells revealed no intra-cytoplasmic secretory granules. The histological changes in renal glomeruli and tubules were improved in N-thioacetylbiguanidine treated group. Use of N-thioacetylbiguanidine characteristically reduced iNOS expression in kidney and renin secretion in JG cells. In conclusion, N-thioacetylbiguanidine is effective in attenuating the histological changes of diabetic nephropathy reaching healing features, which resemble that of a normal kidney
No disponible
Assuntos
Animais , Ratos , Nefropatias Diabéticas/tratamento farmacológico , Biguanidas/farmacocinética , Técnicas Histológicas/métodos , Substâncias Protetoras/farmacocinética , Modelos Animais de DoençasRESUMO
Bacterial nanocellulose (BNC) is chemically identical with plant cellulose but free of byproducts like lignin, pectin, and hemicelluloses, featuring a unique reticulate network of fine fibers. BNC sheets are mostly obtained by static cultivation. Now, a Horizontal Lift Reactor may provide a cost efficient method for mass production. This is of particular interest as BNC features several properties of an ideal wound dressing although it exhibits no bactericidal activity. Therefore, BNC was functionalized with the antiseptics povidone-iodine (PI) and polihexanide (PHMB). Drug loading and release, mechanical characteristics, biocompatibility, and antimicrobial efficacy were investigated. Antiseptics release was based on diffusion and swelling according to Ritger-Peppas equation. PI-loaded BNC demonstrated a delayed release compared to PHMB due to a high molar drug mass and structural changes induced by PI insertion into BNC that also increased the compressive strength of BNC samples. Biological assays demonstrated high biocompatibility of PI-loaded BNC in human keratinocytes but a distinctly lower antimicrobial activity against Staphylococcus aureus compared to PHMB-loaded BNC. Overall, BNC loaded with PHMB demonstrated a better therapeutic window. Moreover, compressive and tensile strength were not changed by incorporation of PHMB into BNC, and solidity during loading and release could be confirmed.
Assuntos
Anti-Infecciosos Locais/administração & dosagem , Biguanidas/administração & dosagem , Celulose , Nanopartículas , Povidona-Iodo/administração & dosagem , Acetobacteraceae/química , Acetobacteraceae/metabolismo , Anti-Infecciosos Locais/farmacocinética , Bandagens , Biguanidas/farmacocinética , Materiais Biocompatíveis/química , Materiais Biocompatíveis/isolamento & purificação , Fenômenos Biomecânicos , Linhagem Celular , Celulose/química , Celulose/isolamento & purificação , Humanos , Teste de Materiais , Nanopartículas/administração & dosagem , Nanopartículas/química , Nanopartículas/ultraestrutura , Povidona-Iodo/farmacocinética , Staphylococcus aureus/efeitos dos fármacosRESUMO
OBJECTIVES: To measure the diffusion of topical preparations of moxifloxacin, amphotericin B (AmB), and polyhexamethylene biguanide (PHMB) through silicone hydrogel (SH) contact lenses (CLs) in vitro. METHODS: Using an in vitro model, the diffusion of three antimicrobials through SH CLs was measured. Diffused compounds were measured using a spectrophotometer at set time points over a period of 4 hr. The amount of each diffused antimicrobial was determined by comparing the experimental value with a standard curve. A biological assay was performed to validate the CL diffusion assay by testing antimicrobial activity of diffused material against lawns of susceptible bacteria (Staphylococcus epidermidis) and yeast (Saccharomyces cerevisiae). Experiments were repeated at least two times with a total of at least four independent replicates. RESULTS: Our data show detectable moxifloxacin and PHMB diffusion through SH CLs at 30 min, whereas AmB diffusion remained below the limit of detection within the 4-hr experimental period. In the biological assay, diffused moxifloxacin demonstrated microbial killing starting at 20 min on bacterial lawns, whereas PHMB and AmB failed to demonstrate killing on microbial lawns over the course of the 60-min experiment. CONCLUSIONS: In vitro diffusion assays demonstrate limited penetration of certain anti-infective agents through SH CLs. Further studies regarding the clinical benefit of using these agents along with bandage CL for corneal pathologic condition are warranted.
Assuntos
Anfotericina B/farmacocinética , Anti-Infecciosos/farmacocinética , Biguanidas/farmacocinética , Lentes de Contato Hidrofílicas , Fluoroquinolonas/farmacocinética , Anfotericina B/farmacologia , Anti-Infecciosos/farmacologia , Biguanidas/farmacologia , Contagem de Colônia Microbiana , Lentes de Contato Hidrofílicas/microbiologia , Difusão , Fluoroquinolonas/farmacologia , Hidrogel de Polietilenoglicol-Dimetacrilato , Moxifloxacina , Saccharomyces cerevisiae/efeitos dos fármacos , Silicones , Espectrofotometria , Staphylococcus epidermidis/efeitos dos fármacosAssuntos
Biguanidas/análise , Soluções para Lentes de Contato/química , Infecções Oculares Fúngicas/etiologia , Fusariose/etiologia , Ceratite/microbiologia , Plásticos/química , Biguanidas/farmacocinética , Cromatografia Líquida , Soluções para Lentes de Contato/efeitos adversos , Fusarium , Temperatura Alta , Humanos , Espectrometria de Massas em TandemRESUMO
Metformin is widely prescribed for the treatment of type II diabetes. Recently, it has been proposed that this compound or related biguanides may have antineoplastic activity. Biguanides may exploit specific metabolic vulnerabilities of transformed cells by acting on them directly, or may act by indirect mechanisms that involve alterations of the host environment. Preclinical data suggest that drug exposure levels are a key determinant of proposed direct actions. With respect to indirect mechanisms, it will be important to determine whether recently demonstrated metformin-induced changes in levels of candidate systemic mediators such as insulin or inflammatory cytokines are of sufficient magnitude to achieve therapeutic benefit. Results of the first generation of clinical trials now in progress are eagerly anticipated. Ongoing investigations may justify a second generation of trials that explore pharmacokinetic optimization, rational drug combinations, synthetic lethality strategies, novel biguanides, and the use of predictive biomarkers.
Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Biguanidas/farmacologia , Neoplasias/tratamento farmacológico , Antimetabólitos Antineoplásicos/farmacocinética , Antimetabólitos Antineoplásicos/uso terapêutico , Biguanidas/farmacocinética , Biguanidas/uso terapêutico , Ensaios Clínicos como Assunto , Resistencia a Medicamentos Antineoplásicos , Sinergismo Farmacológico , Metabolismo Energético , Humanos , Terapia de Alvo Molecular , Neoplasias/metabolismoRESUMO
PURPOSE: Reports on cytotoxic effects of rigid gas-permeable lens multipurpose solutions, which remain important because of increasing popularity of orthokeratology, are limited. This study determined cytotoxic effects of rigid gas-permeable lens multipurpose solutions on human corneal epithelial cells and assessed the proliferation rate at different levels of cell membrane damage. METHODS: The human corneal epithelial cells were exposed to multipurpose solutions containing chlorhexidine gluconate (0.003%) and polyaminopropyl biguanide (PHMB) (0.0005%) (MPS-A), PHMB (0.0005%) (MPS-B) and PHMB (0.0001%) (MPS-C) for one, five and 10 minutes. Following staining with Annexin V-FITC/7-AAD, cell viability and membrane integrity were assessed by flow cytometry. Effects of exposure to concentrations of 10 to 40 per cent multipurpose solutions for 12 hours on the metabolic rate of human corneal epithelial cells were assessed by 3-(4-,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay. Recovery rates were assessed after re-culture for 96 hours at 37°C. RESULTS: MPS-A exposure caused the highest percentage of early and late necrotic cells for all exposure times and was significantly higher than other multipurpose solutions (p < 0.0001). After 10 minutes exposure, almost 40 per cent of cells in MPS-A but less than five per cent in MPS-B or MPS-C, were in late necrotic stage. After 12 hours of exposure, cell activity was significantly reduced in a dose-response manner for MPS-A treated cells only (p > 0.05). After 96 hours of re-culture, all exposed cells showed some reduction in viability but the effects of exposure to 30 and 40 per cent MPS-A resulted in loss of viability. CONCLUSION: The presence of chlorhexidine appeared to increase cytotoxicity of multipurpose solutions for rigid gas-permeable lenses. This was apparent in both increased levels of necrotic cells on initial exposure and reductions in viability after prolonged exposures at lower dilutions. Multipurpose solutions containing PHMB as a preservative, while not causing acute cytotoxicity, did affect cell viability following exposure to diluted solutions. This indicated it is inadvisable to expose the cornea to multipurpose solutions but rather to rinse lenses with saline before insertion and use artificial tears for rewetting.
Assuntos
Soluções para Lentes de Contato/farmacocinética , Soluções para Lentes de Contato/toxicidade , Epitélio Corneano/efeitos dos fármacos , Epitélio Corneano/metabolismo , Anti-Infecciosos Locais/farmacocinética , Anti-Infecciosos Locais/toxicidade , Biguanidas/farmacocinética , Biguanidas/toxicidade , Permeabilidade da Membrana Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Clorexidina/análogos & derivados , Clorexidina/farmacocinética , Clorexidina/toxicidade , Epitélio Corneano/citologia , Citometria de Fluxo , Gases , Humanos , Conservantes Farmacêuticos/farmacocinética , Conservantes Farmacêuticos/toxicidadeRESUMO
Metformin, a widely used anti-hyperglycemic drug in the biguanide class, is currently under investigation for the prevention of cancer. Surprisingly however, considering the time and cost of clinical chemoprevention trials and the current scrutiny of cancer chemoprevention, limited attention has been given to integrating available data, identifying the subpopulations most likely to benefit, or to quantitatively understanding the potential pitfalls of biguanide chemoprevention. Herein, a physiologically-based pharmacokinetic (PBPK) and pharmacodynamic framework is proposed for integrating information on physicochemical, cell-based, animal, and human studies of various biguanides to identify gaps in knowledge and to build a systems model that may facilitate the planning of randomized cancer chemoprevention trials of metformin.
Assuntos
Biguanidas/farmacocinética , Metabolismo Energético/fisiologia , Hipoglicemiantes/farmacocinética , Metformina/farmacocinética , Neoplasias/metabolismo , Estresse Oxidativo/fisiologia , Animais , Biguanidas/farmacologia , Biguanidas/uso terapêutico , Quimioprevenção/métodos , Quimioprevenção/tendências , Metabolismo Energético/efeitos dos fármacos , Humanos , Hipoglicemiantes/farmacologia , Hipoglicemiantes/uso terapêutico , Metformina/farmacologia , Metformina/uso terapêutico , Neoplasias/tratamento farmacológico , Neoplasias/prevenção & controle , Estresse Oxidativo/efeitos dos fármacosRESUMO
Metformin is an oral antihyperglycaemic agent widely used in the management of non-insulin-dependent diabetes mellitus. The liver is the primary target, metformin being taken up into human and rat hepatocytes via an active transport mechanism. The present study was designed to compare hepatic uptake of two biguanides, metformin and phenformin, in vitro and in vivo. In in vitro experiments, performed using rat cryopreserved hepatocytes, phenformin exhibited a much higher affinity and transport than metformin, with marked differences in kinetics. The K(m) values for metformin and phenformin were 404 and 5.17µM, respectively, with CLint (V(max)/K(m)) values 1.58µl/min per 10(6) cells and 34.7µl/min per 10(6) cells. In in vivo experiments, when (14)C-metformin and (14)C-phenformin were given orally to male rats at a dose of 50mg/kg, the liver concentrations of radioactivity at 0.5 hour after dosing were 21.5µg eq./g with metformin but 147.1µg eq./g for phenformin, ratios of liver to plasma concentrations being 4.2 and 61.3, respectively. In conclusion, the results suggest that uptake of biguanides by rat hepatocytes is in line with the liver distribution found in vivo, phenformin being more efficiently taken up by liver than metformin after oral administration.
Assuntos
Biguanidas/farmacocinética , Hipoglicemiantes/farmacocinética , Fígado/metabolismo , Animais , Biguanidas/sangue , Biguanidas/metabolismo , Transporte Biológico Ativo , Biotransformação , Células Cultivadas , Hepatócitos/metabolismo , Hipoglicemiantes/sangue , Hipoglicemiantes/metabolismo , Masculino , Metformina/sangue , Metformina/metabolismo , Metformina/farmacocinética , Fenformin/sangue , Fenformin/metabolismo , Fenformin/farmacocinética , Ratos , Ratos Sprague-Dawley , Organismos Livres de Patógenos Específicos , Distribuição TecidualRESUMO
Type 2 diabetes mellitus (T2DM) is an increasingly prevalent disease. Several classes of drugs are currently available to treat T2DM patients; however, clinical response to these drugs often exhibits significant variation among individuals. For the oral antidiabetic drug classes of sulfonylureas, nonsulfonylurea insulin secretagogs, biguanides and thiazolidinediones, pharmacogenomic evidence has accumulated demonstrating an association between specific gene polymorphisms and interindividual variability in their therapeutic and adverse reaction effects. These polymorphisms are in genes of molecules involved in metabolism, transport and therapeutic mechanisms of the aforementioned drugs. Overall, it appears that pharmacogenomics has the potential to improve the management of T2DM and help clinicians in the effective prescribing of oral antidiabetic medications. Although pharmacogenomics can explain some of the heterogeneity in dose requirements, response and incidence of adverse effects of drugs between individuals, it is now clearly understood that much of the diversity in drug effects cannot be solely explained by studying the genomic diversity. Epigenomics, the field that focuses on nongenomic modifications that influence gene expression, may expand the scope of pharmacogenomics towards optimization of drug therapy. Therefore, pharmacoepigenomics, the combined analysis of genetic variations and epigenetic modifications, holds promise for the realization of personalized medicine. Although pharmacoepigenomics has so far been evaluated mainly in cancer pharmacotherapy, studies on epigenomic modifications during T2DM development provide useful data on the potential of pharmacoepigenomics to elucidate the mechanisms underlying interindividual response to oral antidiabetic treatment. In summary, the present article focuses on available data from pharmacogenomic studies of oral antidiabetic drugs and also provides an overview of T2DM epigenomic research, which has the potential to boost the development of pharmacoepigenomics in antidiabetic treatment.
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/genética , Hipoglicemiantes/farmacologia , Administração Oral , Animais , Biguanidas/farmacocinética , Biguanidas/farmacologia , Sistema Enzimático do Citocromo P-450/genética , Sistema Enzimático do Citocromo P-450/metabolismo , Angiopatias Diabéticas/patologia , Epigenômica , Humanos , Hiperglicemia/genética , Hipoglicemiantes/farmacocinética , Hipoglicemiantes/uso terapêutico , MicroRNAs/genética , Farmacogenética , Polimorfismo Genético/genética , Polimorfismo Genético/fisiologia , Compostos de Sulfonilureia/farmacocinética , Compostos de Sulfonilureia/farmacologia , Tiazolidinedionas/farmacocinética , Tiazolidinedionas/farmacologiaRESUMO
Diabetes mellitus is a leading cause of kidney disease worldwide. A large and expanding array of treatments for diabetes is available to improve glycemic control, including newer classes of drugs, such as thiazolidinediones and incretin-based therapies. The presence of impaired kidney function with reduced glomerular filtration rate should influence choices, dosing, and monitoring of hypoglycemic agents, as some agents require a dosing adjustment in patients with kidney disease and some are entirely contraindicated. This article reviews the clinical use of insulin and other antidiabetic therapies, focusing on pharmacokinetic properties and dosing in patients with advanced kidney disease.
Assuntos
Nefropatias Diabéticas/tratamento farmacológico , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/farmacocinética , Falência Renal Crônica/tratamento farmacológico , Biguanidas/administração & dosagem , Biguanidas/farmacocinética , Inibidores da Dipeptidil Peptidase IV/administração & dosagem , Inibidores da Dipeptidil Peptidase IV/farmacocinética , Peptídeo 1 Semelhante ao Glucagon/administração & dosagem , Peptídeo 1 Semelhante ao Glucagon/farmacocinética , Inibidores de Glicosídeo Hidrolases , Humanos , Insulina/administração & dosagem , Insulina/farmacocinética , Compostos de Sulfonilureia/administração & dosagem , Compostos de Sulfonilureia/farmacocinética , Tiazolidinedionas/administração & dosagem , Tiazolidinedionas/farmacocinéticaRESUMO
Phenoxypropoxybiguanides, such as 1 (PS-15), are prodrugs analogous to the relationship of proguanil and its active metabolite cycloguanil. Unlike cycloguanil, however, 1a (WR99210), the active metabolite of 1, has retained in vitro potency against newly emerging antifolate-resistant malaria parasites. Unfortunately, manufacturing processes and gastrointestinal intolerance have prevented the clinical development of 1. In vitro antimalarial activity and in vitro metabolism studies have been performed on newly synthesized phenoxypropoxybiguanide analogues. All of the active dihydrotriazine metabolites exhibited potent antimalarial activity with in vitro IC(50) values less than 0.04 ng/mL. In vitro metabolism studies in human liver microsomes identified the production of not only the active dihydrotriazine metabolite, but also a desalkylation on the carbonyl chain, and multiple hydroxylated metabolites. The V(max) for production of the active metabolites ranged from 10.8 to 27.7 pmol/min/mg protein with the K(m) ranging from 44.8 to 221 microM. The results of these studies will be used to guide the selection of a lead candidate.
Assuntos
Antimaláricos/farmacocinética , Biguanidas/farmacocinética , Microssomos Hepáticos/metabolismo , Pró-Fármacos/farmacocinética , Triazinas/metabolismo , Animais , Antimaláricos/química , Antimaláricos/metabolismo , Biguanidas/química , Biguanidas/metabolismo , Cromatografia Líquida , Resistência a Medicamentos , Antagonistas do Ácido Fólico/farmacologia , Humanos , Técnicas In Vitro , Espectrometria de Massas , Plasmodium falciparum/efeitos dos fármacos , Pró-Fármacos/química , Pró-Fármacos/metabolismo , Relação Estrutura-AtividadeRESUMO
Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating therapy is held to reflect progressive loss of islet beta-cell function, usually in the presence of obesity-related insulin resistance. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. The main classes are heterogeneous in their modes of action, safety profiles and tolerability. These main classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones). The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated the benefits of intensified glycaemic control on microvascular complications in newly diagnosed patients with type 2 diabetes. However, the picture was less clearcut with regard to macrovascular disease, with neither sulphonylureas nor insulin significantly reducing cardiovascular events. The impact of oral antidiabetic agents on atherosclerosis--beyond expected effects on glycaemic control--is an increasingly important consideration. In the UKPDS, overweight and obese patients randomised to initial monotherapy with metformin experienced significant reductions in myocardial infarction and diabetes-related deaths. Metformin does not promote weight gain and has beneficial effects on several cardiovascular risk factors. Accordingly, metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS. Encouragingly, the recent Steno-2 Study showed that intensive target-driven, multifactorial approach to management, based around a sulphonylurea, reduced the risk of both micro- and macrovascular complications in high-risk patients. Theoretical advantages of selectively targeting postprandial hyperglycaemia require confirmation in clinical trials of drugs with preferential effects on this facet of hyperglycaemia are currently in progress. The insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome; the results of clinical trials with cardiovascular endpoints are awaited. The selection of initial monotherapy is based on a clinical and biochemical assessment of the patient, safety considerations being paramount. In some circumstances, for example pregnancy or severe hepatic or renal impairment, insulin may be the treatment of choice when nonpharmacological measures prove inadequate. Insulin is also required for metabolic decompensation, that is, incipient or actual diabetic ketoacidosis, or non-ketotic hyperosmolar hyperglycaemia. Certain comorbidities, for example presentation with myocardial infarction during other acute intercurrent illness, may make insulin the best option. Oral antidiabetic agents should be initiated at a low dose and titrated up according to glycaemic response, as judged by measurement of glycosylated haemoglobin (HbA1c) concentration, supplemented in some patients by self monitoring of capillary blood glucose. The average glucose-lowering effect of the major classes of oral antidiabetic agents is broadly similar (averaging a 1-2% reduction in HbA1c), alpha-glucosidase inhibitors being rather less effective. Tailoring the treatment to the individual patient is an important principle. Doses are gradually titrated up according to response. However, the maximal glucose-lowering action for sulphonylureas is usually attained at appreciably lower doses (approximately 50%) than the manufacturers' recommended daily maximum. Combinations of certain agents, for example a secretagogue plus a biguanide or a thiazolidinedione, are logical and widely used, and combination preparations are now available in some countries. While the benefits of metformin added to a sulphonylurea were initially less favourable in the UKPDS, longer-term data have allayed concern. When considering long-term therapy, issues such as tolerability and convenience are important additional considerations. Neither sulphonylureas nor biguanides are able to appreciably alter the rate of progression of hyperglycaemia in patients with type 2 diabetes. Preliminary data suggesting that thiazolidinediones may provide better long-term glycaemic stability are currently being tested in clinical trials; current evidence, while encouraging, is not conclusive. Delayed progression from glucose intolerance to type 2 diabetes in high-risk individuals with glucose intolerance has been demonstrated with troglitazone, metformin and acarbose. However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals.
Assuntos
Biguanidas , Diabetes Mellitus Tipo 2/tratamento farmacológico , Inibidores de Glicosídeo Hidrolases , Hipoglicemiantes , Compostos de Sulfonilureia , Tiazolidinedionas , Tiazolidinedionas/uso terapêutico , Biguanidas/efeitos adversos , Biguanidas/farmacocinética , Biguanidas/uso terapêutico , Humanos , Hipoglicemiantes/efeitos adversos , Hipoglicemiantes/farmacocinética , Hipoglicemiantes/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Compostos de Sulfonilureia/efeitos adversos , Compostos de Sulfonilureia/farmacocinética , Compostos de Sulfonilureia/uso terapêutico , Tiazolidinedionas/efeitos adversos , Tiazolidinedionas/farmacocinéticaRESUMO
AIMS: This study investigates the effects of biguanides during encystment of Acanthamoeba castellanii. METHODS AND RESULTS: A non-nutrient encystment system was used to investigate the changes in the levels of sorption (uptake) of three non-cysticidal concentrations (10, 20 and 50 microg ml(-1)) of chlorhexidine diacetate (CHA) and polyhexamethylene biguanide (PHMB) as well as their effects on viability and leakage of pentose sugars during the first 36 h of encystment. Trophozoites treated with CHA or PHMB were more sensitive and generally sorbed more of each biocide than cysts. During encystment, the largest increases in resistance developed between 18 and 36 h for both biguanides with the resistance emerging to biguanide concentrations of 10 or 20 microg ml(-1) between 18 and 24 h. At 50 microg ml(-1) resistance emerged between 24 and 36 h. There was a general decrease in biocide sorption during encystment between 0-24 and 0-21 h for CHA and PHMB, respectively, at a concentration of 50 microg ml(-1). The greatest decline in biguanide-induced pentose leakage was between 0 and 12 h. CONCLUSIONS: The results suggest that during encystment some of the changes in the susceptibility to CHA or PHMB may be related to decreases in the levels of biocide sorption, which is limited by the developing cyst wall. SIGNIFICANCE AND IMPACT OF THE STUDY: During encystation, changes occur in biguanide sensitivity. The physical barrier of the cyst wall may be an important factor in limiting biocide sorption.
Assuntos
Acanthamoeba/efeitos dos fármacos , Amebicidas/farmacologia , Biguanidas/farmacologia , Desinfetantes/farmacologia , Pentoses/metabolismo , Acanthamoeba/metabolismo , Amebicidas/farmacocinética , Animais , Biguanidas/farmacocinética , Clorexidina/farmacocinética , Clorexidina/farmacologia , Desinfetantes/farmacocinética , Relação Dose-Resposta a Droga , Resistência a MedicamentosRESUMO
1. The oxidative one-carbon cleavage reaction in the octyl side chain of olanexidine [1-(3,4-dichlorobenzyl)-5-octylbiguanide], a new potent biguanide antiseptic, was characterized in dog liver microsomes. 2. Olanexidine was initially biotransformed to a monohydroxylated metabolite, 8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-2-octanol (DM-215), and DM-215 was subsequently oxidized to the diol derivative, 8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-1,2-octandiol (DM-220). DM-220 was further biotransformed to 2-hydroxy aldehyde derivative, 2-hydroxy carboxylic acid derivative, and an oxidative C-1-C-2 bond cleavage metabolite, 7-[5-(3,4-dichlorobenzyl)-1-biguanidino] heptanoic acid [DM-223 (C7), a seven-carbon chain derivative], after incubation with dog liver microsomes. 3. DM-223 formation required NADPH as a cofactor and was inhibited by quinidine and quinine, relatively selective inhibitors of CYP2D subfamilies in dogs. 4. The results suggest that the one-carbon fragment of the octyl side chain of olanexidine could be removed by the oxidative C-C bond cleavage with the possible involvement of cytochrome P450 systems such as CYP2D subfamily. This oxidative C-C bond cleavage reaction by cytochrome P450s could play an important role in the removal of one-carbon fragment of other drugs or endogenous compounds containing aliphatic chains.
Assuntos
Anti-Infecciosos/farmacocinética , Biguanidas/farmacocinética , Microssomos Hepáticos/metabolismo , Animais , Anti-Infecciosos/farmacologia , Biguanidas/antagonistas & inibidores , Biguanidas/metabolismo , Biguanidas/farmacologia , Biotransformação , Cromatografia Líquida de Alta Pressão , Inibidores das Enzimas do Citocromo P-450 , Cães , Inibidores Enzimáticos/farmacologia , NADP/metabolismo , Oxirredução , Quinidina/farmacologia , Quinina/farmacologia , Espectrometria de Massas por Ionização por ElectrosprayRESUMO
Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements. Insulin resistance is the most prominent feature common in both type 2 diabetes and its associated metabolic abnormalities. Until 1995, the only therapeutic interventions available in the United States were the insulin secretagogues sulfonylureas and insulin. With the introduction of metformin in the United States in the mid-1990s and the subsequent advent of thiazolidinediones, an opportunity exists to address and directly reverse, at least in part, the defects in insulin action seen in individuals with type 2 diabetes. Evidence shows that insulin sensitizers not only have beneficial effects on glycemic control but also have multiple effects on lipid metabolism and atherosclerotic vascular processes that could prove to be beneficial. We discuss safety issues of these agents, their potential use in preventing onset and progression of diabetes, and their use in other related metabolic conditions such as polycystic ovary syndrome.
Assuntos
Biguanidas/uso terapêutico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Resistência à Insulina , Tiazóis/uso terapêutico , Tiazolidinedionas , Biguanidas/farmacocinética , Doenças Cardiovasculares/prevenção & controle , Humanos , Hipoglicemiantes/farmacocinética , Ligantes , Tiazóis/farmacocinéticaRESUMO
BACKGROUND: Bacterial vaginosis (BV) is the most common vulvovaginal infection and represents the 35% of all the infections occurring in women in the reproductive age. It is well recognised that serious forms of BV can induce several complications among women undergoing gynaecologic or obstetric surgery, having pelvic inflammatory diseases, temporary or absolute infertility, miscarriage and abortion. At present, the clinical treatment of choice of BV is the use of systemic or local (gel or cream) metronidazole and clindamycin, though systemic use has some limitations due to side-effects and contraindications. Polyhexamethylene biguanide (PHMB) is a new bi-biguanide compound having a broad spectrum activity and low toxicity, that have been successfully utilized in ophthalmology and dentistry. Aim of this study was to evaluate the efficacy and tolerability of a single-dose vaginal administration of a PHMB vaginal gel in the treatment of BV in comparison to clindamycin vaginal cream. METHODS: One-hundred and ten patients affected by BV were treated with PHMB vaginal gel in single administration or clindamycin vaginal cream 1 daily administration for 7 days. RESULTS: We demonstrated the therapeutic efficacy of mono-dose administration of a vaginal solution containing PHMB in BV treatment; this efficacy is similar to the one shown in antibiotic therapy. Furthermore, this product was well tolerated by all treated patients. CONCLUSIONS: Mono-dose PHMB treatment should be regarded as the therapy of choice for BV, using clindamycin and metronidazole only for relapses treatment.